Skip to search formSkip to main contentSkip to account menu

vismodegib

Known as: Vismodegibum 
An orally bioavailable small molecule with potential antineoplastic activity. Hedgehog antagonist GDC-0449 targets the Hedgehog signaling pathway… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

ErivedgeGDC-0449

Broader (1)

HhAntag691
NCIt Antineoplastic Agent Terminologyvismodegib 150 MG Oral Capsule

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Vismodegib treatment in a HIV positive patient on antiretroviral therapy
Observation: We report a case of a 64 year old man presented with a 3 year history of ulcerative basal cell carcinoma involving… 
Highly Cited
2017
Highly Cited
2017
Corrigendum: Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma
Scientific Reports 7: Article number: 44079; published online: 09 March 2017; updated: 21 April 2017. In this Article, Monika… 
2017
2017
Smoothened antagonist GDC-0449 (Vismodegib) inhibits proliferation and triggers apoptosis in colon cancer cell lines.
The sonic hedgehog (Shh) pathway has been proven to be involved in embryonic development and cancer growth. GDC-0449, an… 
2016
2016
An unusual case of basal cell carcinoma of the vulva with lung metastases
2016
2016
Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study.
BACKGROUND MicroRNAs (miRNAs) have been identified as key players in posttranscriptional gene regulation and have a significant… 
2015
2015
Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
2015
2015
Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.
2015
2015
[Locally advanced basal-cell carcinoma: Combined alternative treatments beyond surgery].
2012
2012
Hedgehog hopes lifted by approval... and stung by failure
2012
2012
A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim…
4022 Background: Sonic Hh (SHh), the ligand for the Hh pathway, is over-expressed in >80% of PC. V, a small molecule antagonist… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)